Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

“It's called GLP one receptor,” said Atul Malhotra, MD from the UC San Diego School of Medicine. It’s already FDA-approved to ...

New research being presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that ...

Adults with obesity who used medication and received guidance on resistance training and nutrition lost substantially more ...

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have become household names in recent ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that women are much more aware of knowledgeable about the obesity drugs GLP-1/GIP ...

Fridays offers a subscription-based weight loss service. Its program includes virtual consultations with a health care provider, compounded GLP-1 medications, lifestyle and nutrition coaching, and ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...